Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.00 0.09% 11,060.00 11,038.00 11,040.00 11,176.00 11,002.00 11,034.00 2,453,557 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,668.9 -196.0 5.9 1,653.6 171,332

Astrazeneca Share Discussion Threads

Showing 5676 to 5697 of 5825 messages
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

(END) Dow Jones Newswires

June 27, 2022 02:40 ET (06:40 GMT)

the grumpy old men
AstraZeneca's Wilson disease treatment shows promise in phase 3 trials

Thu, 23rd Jun 2022 15:59
Alliance News

(Alliance News) - AstraZeneca PLC on Thursday reported strong results

from phase III clinical trials for ALXN1840.

The Cambridge-based pharmaceutical company said the FoCus phase III trial of its once-daily, investigational oral medicine

ALXN1840 met its primary endpoint in the treatment of Wilson disease.

Wilson disease is an inherited condition which results in excess copper levels in the liver, brain and other organs. This leads to damage which can greatly impact those with the disease.

ALXN1840 showed copper mobilisation from tissues three-times greater than the standard of care arm.


experienced rapid copper mobilisation, with a response at four weeks, which was sustained through 48 weeks.

ALXN1840 is a novel molecule designed to bind to copper and remove it from the body's tissue and blood.

Shares in AZ were up 0.6% to 10,368.00 pence each in London on Thursday afternoon.

Two mechanistic trials in Wilson disease are underway, and AZ's rare disease group Alexion is working with global health authorities to submit the data for review.

By Elizabeth Winter;

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
The only thing that matters is a transfer of power from the west to the east. Short term gov. vs long term gov.
CWD is now in 27 states of the USA and spreading into Canada

A novel field test for CWD ( Prion Disease)
The University of Minnesota researchers develop novel, field-deployable test for CWD


However the spread of CWD continues unabated due to various stupid/illegal actions


Neutral another word for sell.

UBS cuts Astrazeneca to 'neutral' (buy) - price target 10,100 (10,500) pence

AstraZeneca PLC said Wednesday that trials on high-risk patients showed that the Evusheld drug provides significant protection against Covid-19.

The pharmaceutical company said that a single dose of Evusheld reduced the risk of progressing to severe Covid-19 or death by 50% in non-hospitalized patients with mild-to-moderate Covid-19. In those who received treatment within three days of symptom onset, the medicine reduced the risk by 88%.

The Tackle Phase 3 trial involved 903 adults across the U.S., Latin America, Europe and Japan.

"We are discussing the Tackle data with regulatory authorities and continue to progress submissions in both treatment and prophylaxis indications to help combat Covid-19 on all fronts," Executive Vice President Mene Pangalos said.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

(END) Dow Jones Newswires

June 08, 2022 02:45 ET (06:45 GMT)

Remember brokers have their own agendas for their clients to buy/sell that chart showing as lower highs and lower lows?...
and this..

06/06/2022 | 07:38am EDT

Already positive, the research from JP Morgan and its analyst James Gordon still consider the stock as a Buy opportunity. The target price is unchanged and still at GBX 12000.

Was this downgraded by a broker today?Most likely it'll bounce back tomorrow.
AstraZeneca PLC said Monday that its Covid-19 vaccine has been granted approval in the European Union as a third dose booster for adults.

The pharmaceutical company said that its Vaxzevria vaccine can now be used as a third dose booster in patients previously given a vaccine schedule of either Vaxzevria or other EU-approved vaccines.

"Although more than 65% of the global population has received at least one dose of a Covid-19 vaccine, there remains a significant challenge to ensure people receive both their primary vaccine schedule and third-dose booster, and healthcare professionals now have greater flexibility in their choice of vaccine," AstraZeneca said.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

(END) Dow Jones Newswires

May 23, 2022 02:48 ET (06:48 GMT)

AstraZeneca was suffering from a broker downgrade, as Kepler Cheuvreux cut the parmaceutical stock to 'hold' from 'buy'. Astra shares were down 1.6%.

tp 10500p

Upwards start of upward movement.GDR potential multibagger. 300 nurses trying for new test .
AstraZeneca PLC said Thursday that its treatment for neuromyelitis optica spectrum disorder (NMOSD) Ultomiris met the primary endpoint in a Phase 3 clinical trial with a "statistically significant and clinically meaningful" reduction in the risk of relapse.

The Anglo-Swedish pharma giant said no relapse was observed in 58 patients during a treatment duration of 73 weeks.

"Every NMOSD relapse can have debilitating and irreversible consequences, so reducing relapses is critical," lead primary investigator in the trial Sean J. Pittock said.

The company said the data will be submitted to global health authorities as rapidly as possible.

Write to Michael Susin at

(END) Dow Jones Newswires

May 05, 2022 02:37 ET (06:37 GMT)

Dominic Lunn from Credit Suisse retains his positive opinion on the stock with a Buy rating.

The target price is unchanged at GBX 11000.

AstraZeneca's recent progress in drug innovations makes it a particularly strong choice for delivery of growth and inflation protection:


10,536 -0.25%

adrian j boris
29 Apr '22 - 09:45 - 5558 of 5559
0 0 0
What on earth is this guy chatting about?

Shows what poorly researched inaccurate nonsense is banded about online:


adrian j boris
AstraZeneca plans new US R&D hub as revenues rocket
Phil Taylor
April 29, 2022

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and heart failure therapy Farxiga.

The new site will be at Kendall Square and will serve as the new corporate headquarters for Alexion – which is currently based across the Charles River in Boston’s Seaport District – as well as housing around 1,500 R&D staff from AZ and Alexion in a new purpose-built space.

The site is expected to be completed in 2026 and according to AZ will benefit from its close proximity to several major academic, pharma and biotech institutions, providing access to “future talent”.

Boston and Cambridge are a life sciences hotspot in the US, home to more than 1,000 R&D-based biotechnology companies, with Kendall Square having the greatest density.

News of the investment comes shortly after AZ completed its new headquarters across the Atlantic in Cambridge in the UK, which was built at a cost of around $1.3 billion, three times the original estimate when the project was announced in 2013.

“Today’s announcement is a milestone moment following the acquisition of Alexion in July 2021,” said AZ chief executive Pascal Soriot as the company reported first-quarter sales up 60% to $11.4 billion.

“Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation,” he added.

The healthy sales increase was bolstered by the timing of orders for AZ’s COVID-19 vaccine Vaxzevria, which made $1.1 billion in the quarter but is expected to make less of a contribution in the remainder of the year.

Another $469 million from Evusheld (tixagevimab and cilgavimab), the first drug to be authorised for prevention of COVID-19 infections, although that cam in slightly below analyst expectations.

Soriot also highlighted to performance of Farxiga (dapagliflozin), AZ’s SGLT2 inhibit for diabetes, heart failure and chronic kidney disease, which made $1 billion in the quarter, with a higher-than-predicted rise of 60% over the same period of 2021.

AZ’s oncology franchise also put in a good showing, collectively rising 14% to $3.4 billion, with highly-anticipated new HER2 drug Enhertu (trastuzumab deruxtecan) almost doubling to $76 million in the quarter, with potential new indications promising to accelerate growth further.

There was a 20% gain for Alexion’s Ultomiris (ravulizumab) to $419 million, welcome news as the drug is a successor to successor to Soliris (eculizumab) which slipped 5% to $990 million.

Ultomiris has just become the first and only long-acting C5 inhibitor approved for generalised myasthenia gravis in the US.

Don't miss your daily pharmaphorum news.

adrian j boris
Chat Pages: 233  232  231  230  229  228  227  226  225  224  223  222  Older
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221129 21:52:47